REG - Oxford Cannabinoid - Data from pre-clinical study show positive results

Oxford Cannabinoid Technologies HoldingsAnnouncement

08/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220308:nRSH9363Da&default-theme=true

RNS Number : 9363D  Oxford Cannabinoid Tech.Holdings  08 March 2022

8 March 2022

Oxford Cannabinoid Technologies Holdings plc

("OCTP", or the "Company")

Data from pre-clinical study of OCT461201 shows positive results

 

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the
pharmaceutical company developing prescription cannabinoid medicines targeting
the US$ multi-billion pain market is pleased to announce positive results from
a pre-clinical pain study for its lead compound, OCT461201, targeting the
global Chemotherapy Induced Peripheral Neuropathy ("CIPN") treatment market
valued at US$1.61bn in 2020 and forecasted to reach US$2.37bn by the year
2027.

 

CIPN is a peripheral neuropathy resulting from the neurotoxic effects of
common chemotherapeutic drugs. The hallmarks of CIPN are pain, numbness and
tingling in the extremities. On average, an estimated 60 per cent. of people
undergoing chemotherapy are affected by CIPN at 3 months.  CIPN can be
progressive and enduring, leading to years of debilitation and suffering.

The results from OCTP's recent study show that OCT461201 successfully reduces
pain in a pre-clinical animal model of CIPN induced by paclitaxel, a widely
used chemotherapy agent. Two common symptoms of CIPN are pain caused by
innocuous stimuli, like light touch (mechanical allodynia) and heat or cold
(thermal hyperalgesia).  In the study, OCT461201 significantly reduced pain
from both mechanical allodynia and thermal hyperalgesia compared to untreated
animals.

Globally, there is an urgent need for new therapies to treat CIPN as there are
currently no approved therapies for this condition. The current standard of
care is the off-label use of gabapentinoids (gabapentin and pregabalin) and
antidepressants (e.g. duloxetine), drugs associated with serious side effects.
Furthermore, in some cases their overall clinical effectiveness is inadequate,
leaving cancer patients in pain, with a reduced quality of life and the
prospect of having to change or stop their chemotherapy altogether.

Commenting on the results of the experiment, OCTP Chief Executive John Lucas
said:

"To obtain such a positive result in this study is significant and provides
further evidence that OCT461201 could be an effective therapy in the treatment
of CIPN in cancer patients. Based on previously completed pre-clinical safety
experiments, the Directors believe the administered dose of OCT461201 could
have been increased by over three times. The results of this study demonstrate
the opportunities open to OCT461201 in treating a major and common side effect
experienced by so many cancer patients and we are more excited than ever to be
starting phase 1 clinical trials early next year. These latest results
reaffirm the potential of OCT461201 across multiple indications."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Dr John Lucas (CEO)                           john@oxcantech.com

 Clarissa Sowemimo-Coker (COO)                 clarissa@oxcantech.com

 Cairn Financial Advisers

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Walbrook PR Limited                           +44 (0)20 7933 8780

 Paul Vann                                     +44 (0)7768 807631

 Nicholas Johnson                              oxcantech@walbrookpr.com

 Harbor Access LLC (US/OTCB enquiries)

 Jonathan Paterson                             +1 (203) 862 0492

 Richard Leighton                              Richard.Leighton@harboraccessllc.com

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc is the holding company of Oxford
Cannabinoid Technologies Ltd, a pharmaceutical company developing prescription
cannabinoid medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together the
"Group"). Cannabinoids are compounds found in the cannabis plant that have
been shown to have a range of therapeutic effects on the body, including pain
relief. The Group has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through clinical trials to
gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals
to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst
ensuring market exclusivity around all its key activities. The Group's lead
compound, OCT461201, is a highly potent and selective CB2 agonist and is being
developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical
testing and development with clinical trials scheduled for Q1 2023. The
Group's product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of rare
diseases and includes chemically modified phytocannabinoids with improved
drug-like characteristics and a proprietary library of cannabinoids.

OCTP operates a partnership model with external academic and commercial
partners. (https://www.oxcantech.com/ (https://www.oxcantech.com/) )

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESUPUPCWUPPGBM